Mayne Pharma, Actavis deal

Actavis returned to Mayne rights to Doryx doxycycline and related assets for $50 million. Doryx is a delayed-release pelletized doxycycline that is approved to treat severe acne. Actavis will package, distribute and promote Doryx until May 2, when the business will be transferred to Mayne. ...